Peroxisome Proliferator-Activated Receptor-Gamma 1 Gene Therapy Attenuates Atherosclerosis And Stabilizes Plaques In Apolipoprotein E-Deficient Mice
Qin Hu,Xian Jun Zhang,Cheng Zhang,Yu Xia Zhao,Hong He,Chun Xi Liu,Jin Bo Feng,Hong Jiang,Fa Lin Yang,Chun Xiang Zhang,Yun Zhang
DOI: https://doi.org/10.1089/hum.2007.0142
2008-01-01
Human Gene Therapy
Abstract:Peroxisome proliferator-activated receptor-gamma 1 (PPAR gamma 1) is an important transcription factor involved in atherosclerosis progression. Thus, PPAR gamma 1 appears to be an interesting gene therapeutic target to favorably affect atherosclerosis development. The present study was carried out to test the hypothesis that PPAR gamma 1 gene therapy may attenuate and stabilize atherosclerotic plaques in apolipoprotein E-knockout mice. The recombinant adenovirus carrying mouse PPAR gamma 1 cDNA (AdPPAR gamma 1) was constructed and AdPPAR gamma 1 (5 x 10(8) PFU) or AdGFP (5 x 10(8) PFU), diluted to a total volume of 200 mu l, was injected into the tail vein of mice ( 40 weeks of age and fed a high-fat diet) in two intervention groups (n = 20 each). Mice (n = 20) injected with phosphate-buffered saline (PBS) served as vehicle controls. The results showed that 4-week treatment with AdPPAR gamma 1 attenuated atherosclerotic lesions, although the overall mRNA levels of CD36 were increased in the AdPPAR gamma 1 group. Moreover, PPAR gamma 1 gene overexpression stabilized atherosclerotic plaques as shown by the reduced depositions of lipids and macrophages and increased contents of smooth muscle cells and collagen within the plaques. In addition, marked upregulation of the mRNA levels of cholesterol efflux-related molecules such as liver X receptor alpha and ATP-binding cassette transporter A1 in liver, and downregulation of matrix metalloproteinase-9, human tissue factor, CD40, CD40 ligand, tumor necrosis factor-alpha, monocyte chemoattractant protein-1, vascular cell adhesion molecule-1, macrosialin, class A scavenger receptor, and macrophage migration inhibitory factor in aorta, were demonstrated in AdPPAR gamma 1-treated animals. In contrast, there was no significant difference in aforementioned parameters between the AdGFP and PBS groups. In conclusion, overexpression of the PPAR gamma 1 gene exerts beneficial effects in attenuating atherosclerosis progression and stabilizes vulnerable plaques. Thus, PPAR gamma 1 might offer a promising gene therapeutic target against atherosclerosis.